Effects of YJA20379-4 on Gastric Secretion, Helicobacter pylori Growth and Various Gastric and Duodenal Lesions in Rats
スポンサーリンク
概要
- 論文の詳細を見る
Effects of a newly synthesized antiulcer agent, YJA20379-4,on gastric proton pump (H^+/K^+-ATPase)activity, Helicobacter pylori (H. pylori) growth, gastric acid secretion, and gastro-duodenal lesions, were examined in comparison with those of omeprazole. YJA20379-4 markedly inhibited the H^+/K^+-ATPase activity in a concentration-dependent manner and the inhibitory effect was invreased under a weak acidic condition; the IC_<50> values were 32 and 81 μM at pH 6.4 and 7.4,respectively. The inhibition was completely antagonized by 0.5 mM dithiothretiol (DTT). In addition, YJA20379-4 showed a significant anti-H. pylori activity determined by the agar dilution method. The value of minimum inhibitory concentration (MIC, 3.9-11.7 μg/ml) was at least 3 times more potent than that of omeprazole. In pylorus ligated rats, YJA20379-4 inhibited basal gastric acid secretion when administered by the intraduodenal route (ED_<50> : 23.6 mg/kg). In experimental ulcer models, YJA20379-4 administered by the oral route dose-dependently prevented the development of gastro-duodenal lesions in rats. Moreover, repeated administration of YJA20379-4 promoted the healing of gastric ulcers induced by acetic acid. On the basis of the data obtained, it is suggested that YJA20379-4 has a wide spectrum of antiulcer activities, and its mode of antiulcer actions is dependent on the inhibition of H^+/K^+-ATPase activity and H. pylori growth and the enhancement of a mucosal defense. Thus, YJA20379-4 might prove to be a beneficial therapy for gastritis and peptic ulcer diseases.
- 公益社団法人日本薬学会の論文
- 1998-05-15
著者
-
Kim K‐b
Yungjin Pharmaceutical Co. Ltd. Kyunggi‐do Kor
-
Chung Young-kuk
永進薬品工業株式会社
-
Choi Wahn-soo
永進薬品工業株式会社
-
SOHN Sang-Kwon
永進薬品工業株式会社
-
CHANG Man-Sik
永進薬品工業株式会社
-
WOO Tae-Wook
永進薬品工業株式会社
-
WOO Tae-Wook
Pharmacology and Toxicology Laboratory, Research and Development Center, Yung-Jin Pharmaceutical Co.
-
CHANG Man-Sik
Pharmacology and Toxicology Laboratory, Research and Development Center, Yung-Jin Pharmaceutical Co.
-
CHUNG Young-Kuk
Pharmacology and Toxicology Laboratory, Research and Development Center, Yung-Jin Pharmaceutical Co.
-
KIM Kyu-Bong
Pharmacology and Toxicology Laboratory, Research and Development Center, Yung-Jin Pharmaceutical Co.
-
SOHN Sang-Kwon
Pharmacology and Toxicology Laboratory, Research and Development Center, Yung-Jin Pharmaceutical Co.
-
KIM Sung-Gyu
Pharmacology and Toxicology Laboratory, Research and Development Center, Yung-Jin Pharmaceutical Co.
-
CHOI Wahn-Soo
Pharmacology and Toxicology Laboratory, Research and Development Center, Yung-Jin Pharmaceutical Co.
-
Kim Sung-gyu
Pharmacology And Toxicology Laboratory Research And Development Center Yung-jin Pharmaceutical Co. L
関連論文
- The Single Dose Toxicity of 3-Butyryl-4-[5-(r)-(+)-methylbenzylamino]-8-ethoxy-1, 7-naphthyridine (YJA20379-8) in Rats
- The Single dose Toxicity of 2-Dimethylamino-4, 5-dihydrothiazolo [4', 5':3, 4] pyrido [1, 2-a] benzimidazole (YJA20379-2) in Rats
- The Single Dose Toxicity of 2-Amino-4, 5-dihydro-8-phenylimidazo (2, 1-b) thiazolo (5, 4-g) benzothiazole (YJA20379-1) in Rats
- Effects of YJA20379-4 on Gastric Secretion, Helicobacter pylori Growth and Various Gastric and Duodenal Lesions in Rats